Show simple item record

dc.contributor.authorEvans, Marken
dc.contributor.authorAntonio, Cerielloen
dc.contributor.authorDanne, Thomasen
dc.contributor.authorDe Block, Christopheen
dc.contributor.authorDeVries, Hansen
dc.contributor.authorLind, Marcusen
dc.contributor.authorMathieu, Chantalen
dc.contributor.authorNørgaard, Kirtsenen
dc.contributor.authorRenard, Ericen
dc.contributor.authorWilmot, Emmaen
dc.date.accessioned2019-06-03T23:30:28Z
dc.date.available2019-06-03T23:30:28Z
dc.identifier.issn1462-8902
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/293324
dc.description.abstractFast-acting insulin aspart (faster aspart) is a novel formulation of insulin aspart (IAsp) containing the additional excipients niacinamide and L‐arginine. The improved pharmacological profile and greater early glucose-lowering action of faster aspart compared with IAsp suggests that faster aspart may be advantageous for people with diabetes using continuous subcutaneous insulin infusion (CSII). The recent onset 5 trial was the first to evaluate the efficacy and safety of an ultra-fast-acting insulin in CSII therapy in a large number of participants with type 1 diabetes (T1D). Faster aspart was confirmed to be non-inferior to IAsp in terms of HbA1c reduction and demonstrated significantly improved postprandial glucose control after a standardized meal test without an increased risk of overall severe or blood glucose-confirmed hypoglycaemia. This review summarizes the available clinical evidence for faster aspart administered via CSII and highlights practical considerations based on clinical experience that may help healthcare providers and people with T1D successfully initiate and adjust faster aspart in CSII.
dc.publisherBlackwell Publishing Inc.
dc.rightsAll rights reserved
dc.rights.uri
dc.titleUse of fast-acting insulin aspart in insulin pump therapy in clinical practiceen
dc.typeArticle
prism.publicationNameDiabetes, Obesity and Metabolismen
dc.identifier.doi10.17863/CAM.40478
dcterms.dateAccepted2019-05-28en
rioxxterms.versionofrecord10.1111/dom.13798en
rioxxterms.versionAM
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2019-05-28en
dc.contributor.orcidEvans, Mark [0000-0001-8122-8987]
dc.identifier.eissn1463-1326
rioxxterms.typeJournal Article/Reviewen
cam.issuedOnline2019-05-30en
cam.orpheus.successThu Jan 30 10:44:28 GMT 2020 - Embargo updated*
rioxxterms.freetoread.startdate2020-05-30


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record